Incyte Corporation (NASDAQ:INCY) announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with pembrolizumab (Keytruda®)*, Merck’s anti-PD-1 therapy, have been published as a poster at the European Society for Medical Oncology (ESMO) Annual Congress 2016 in Copenhagen, Denmark.

Further to the previously published abstract, today’s updated data show that among patients with treatment-naïve advanced melanoma (n=19), the combination of epacadostat plus pembrolizumab resulted in progression-free survival (PFS) rates of 74 percent and 57 percent at 6 months and 12 months, respectively. Median PFS has not been reached. The updated data also show an increase in the complete response (CR) rate to 26 percent. The objective response rate (ORR) and disease control rate (DCR) remained consistent with the previously published abstract data, at 58 percent and 74 percent, respectively. All responses are confirmed and ongoing (median follow-up among responders 56 plus [range of 46 to 90 plus] weeks).

“We are excited to share further data with additional follow-up from the Phase 1 portion of the ECHO-202 study,” said Steven Stein, M.D., Incyte’s Chief Medical Officer. “The durable responses seen in patients with treatment-naïve advanced or metastatic melanoma reaffirm the activity of this immunotherapy combination, and we look forward to the read-out of ECHO-301, the ongoing, pivotal Phase 3 trial.”

Epacadostat in combination with pembrolizumab was well tolerated in the Phase 1 population (n=62). The most common (≥15%) all grade treatment-related AEs (TRAEs) were fatigue, rash, pruritus, arthralgia, diarrhea and nausea. Grade ≥3 TRAEs were observed in 19 percent of patients; the most common were rash (8%) and increased lipase (5%). Five patients (8%) discontinued treatment due to TRAEs. (Original Source)

Shares of Incyte are currently trading at $95.52, up $0.74 or 0.78%. INCY has a 1-year high of $124.98 and a 1-year low of $55. The stock’s 50-day moving average is $83.45 and its 200-day moving average is $80.25.

On the ratings front, INCY stock has been the subject of a number of recent research reports. In a report issued on October 5, Jefferies analyst Brian Abrahams maintained a Buy rating on INCY, with a price target of $109, which implies an upside of 15% from current levels. Separately, on October 4, Cowen’s Eric Schmidt reiterated a Buy rating on the stock.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brian Abrahams and Eric Schmidt have a total average return of 8.6% and 22.7% respectively. Abrahams has a success rate of 54% and is ranked #317 out of 4190 analysts, while Schmidt has a success rate of 53.5% and is ranked #69.

The street is mostly Bullish on INCY stock. Out of 12 analysts who cover the stock, 12 suggest a Buy rating . The 12-month average price target assigned to the stock is $103.00, which represents a potential upside of 8.7% from where the stock is currently trading.

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers.